Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 3.83
SCYX's Cash-to-Debt is ranked higher than
52% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. SCYX: 3.83 )
Ranked among companies with meaningful Cash-to-Debt only.
SCYX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 9999.5 Max: No Debt
Current: 3.83
Equity-to-Asset 0.59
SCYX's Equity-to-Asset is ranked lower than
59% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SCYX: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
SCYX' s Equity-to-Asset Range Over the Past 10 Years
Min: -8.42  Med: 0.83 Max: 0.89
Current: 0.59
-8.42
0.89
Piotroski F-Score: 3
Altman Z-Score: -3.97
Beneish M-Score: -3.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -10398.83
SCYX's Operating Margin % is ranked lower than
97% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. SCYX: -10398.83 )
Ranked among companies with meaningful Operating Margin % only.
SCYX' s Operating Margin % Range Over the Past 10 Years
Min: -11030.74  Med: -63.67 Max: -42.74
Current: -10398.83
-11030.74
-42.74
Net Margin % -10810.16
SCYX's Net Margin % is ranked lower than
97% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. SCYX: -10810.16 )
Ranked among companies with meaningful Net Margin % only.
SCYX' s Net Margin % Range Over the Past 10 Years
Min: -12693.77  Med: -180.7 Max: -22.26
Current: -10810.16
-12693.77
-22.26
ROE % -76.68
SCYX's ROE % is ranked lower than
91% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. SCYX: -76.68 )
Ranked among companies with meaningful ROE % only.
SCYX' s ROE % Range Over the Past 10 Years
Min: -86.56  Med: -78.13 Max: -47.45
Current: -76.68
-86.56
-47.45
ROA % -50.93
SCYX's ROA % is ranked lower than
90% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. SCYX: -50.93 )
Ranked among companies with meaningful ROA % only.
SCYX' s ROA % Range Over the Past 10 Years
Min: -248.08  Med: -73.36 Max: -16.25
Current: -50.93
-248.08
-16.25
GuruFocus has detected 4 Warning Signs with SCYNEXIS Inc $SCYX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SCYX's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:SCYX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:EVOK, OTCPK:IMLFF, NAS:JNP, OTCPK:NRIFF, NAS:FCSC, OTCPK:STNY, NAS:BPTH, NAS:PTX, OTCPK:MGWFF, OTCPK:MRPHF, NAS:OREX, OTCPK:ITHUF, NAS:SNOA, OTCPK:SENZ, OTCPK:CVSI, OTCPK:KAYS, OTCPK:GLDFF, NAS:MEIP, OTCPK:SPLIF, NAS:BNTC » details
Traded in other countries:135.Germany,
Headquarter Location:USA
SCYNEXIS Inc is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs.

SCYNEXIS Inc was incorporated in Delaware in November 4, 1999 as ScyRex, Inc. In June 2002, the Company changed its name to SCYNEXIS Inc. It is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs. The Company is developing its product candidate SCY-078, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, it has a clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases. It also provides contract research and development services in the field of animal health. The Company's competitors include pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic drug companies.

Top Ranked Articles about SCYNEXIS Inc

Potent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC)
SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXIS, Inc. (SCYX) & Lead Plaintiff Deadline - May 8, 2017
DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In SCYNEXIS, Inc. (Nasdaq: SCYX) To Contact The Firm
UPCOMING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infective Candidate SCY-078
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in SCYNEXIS, Inc. of Class Action Lawsuit and Upcoming Deadline – SCYX
SCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID
SCYX LOSS NOTICE: Rosen Law Firm Reminds SCYNEXIS, Inc. Investors of Important Deadline in Class Action – SCYX

Ratios

vs
industry
vs
history
PB Ratio 1.24
SCYX's PB Ratio is ranked higher than
67% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. SCYX: 1.24 )
Ranked among companies with meaningful PB Ratio only.
SCYX' s PB Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.99 Max: 3.5
Current: 1.24
1.08
3.5
PS Ratio 124.62
SCYX's PS Ratio is ranked lower than
97% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. SCYX: 124.62 )
Ranked among companies with meaningful PS Ratio only.
SCYX' s PS Ratio Range Over the Past 10 Years
Min: 0.39  Med: 9.31 Max: 291.76
Current: 124.62
0.39
291.76
EV-to-EBIT -0.05
SCYX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. SCYX: -0.05 )
Ranked among companies with meaningful EV-to-EBIT only.
SCYX' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.3  Med: -1.4 Max: 0.7
Current: -0.05
-19.3
0.7
EV-to-EBITDA -0.05
SCYX's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. SCYX: -0.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCYX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.5  Med: -1.4 Max: 0.7
Current: -0.05
-27.5
0.7
Current Ratio 16.55
SCYX's Current Ratio is ranked higher than
96% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. SCYX: 16.55 )
Ranked among companies with meaningful Current Ratio only.
SCYX' s Current Ratio Range Over the Past 10 Years
Min: 0.11  Med: 9.77 Max: 16.55
Current: 16.55
0.11
16.55
Quick Ratio 16.55
SCYX's Quick Ratio is ranked higher than
96% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. SCYX: 16.55 )
Ranked among companies with meaningful Quick Ratio only.
SCYX' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 9.77 Max: 16.55
Current: 16.55
0.11
16.55
Days Sales Outstanding 359.30
SCYX's Days Sales Outstanding is ranked lower than
97% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. SCYX: 359.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCYX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.57  Med: 36.01 Max: 1320.82
Current: 359.3
15.57
1320.82

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.31
SCYX's Price-to-Net-Cash is ranked higher than
94% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. SCYX: 1.31 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SCYX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 2.23 Max: 3.69
Current: 1.31
0
3.69
Price-to-Net-Current-Asset-Value 1.28
SCYX's Price-to-Net-Current-Asset-Value is ranked higher than
91% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. SCYX: 1.28 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SCYX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 2.1 Max: 3.46
Current: 1.28
0
3.46
Price-to-Tangible-Book 1.24
SCYX's Price-to-Tangible-Book is ranked higher than
73% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. SCYX: 1.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SCYX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 2.06 Max: 2.73
Current: 1.24
1.16
2.73
Price-to-Median-PS-Value 13.50
SCYX's Price-to-Median-PS-Value is ranked lower than
93% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. SCYX: 13.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SCYX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.01 Max: 39.88
Current: 13.5
0
39.88
Earnings Yield (Greenblatt) % -1862.43
SCYX's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. SCYX: -1862.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SCYX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11403.94  Med: 258.15 Max: 4720.2
Current: -1862.43
-11403.94
4720.2

More Statistics

Revenue (TTM) (Mil) $0.26
EPS (TTM) $ -1.34
Beta0.40
Short Percentage of Float9.90%
52-Week Range $1.55 - 5.51
Shares Outstanding (Mil)25.80

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.55 -2.08 -2.08
EPS without NRI ($) -1.55 -2.08 -2.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SCYX

Headlines

Articles On GuruFocus.com
Potent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candi May 11 2017 
SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Developm May 08 2017 
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXI May 08 2017 
DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And May 03 2017 
UPCOMING DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. Apr 28 2017 
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against SCYNEXIS, I Apr 28 2017 
DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. a Apr 27 2017 
APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. Apr 25 2017 
Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS’ Lead Anti-infe Apr 25 2017 
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Apr 24 2017 

More From Other Websites
ETFs with exposure to SCYNEXIS, Inc. : May 15, 2017 May 15 2017
SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
Potent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida... May 11 2017
Scynexis reports 1Q loss May 08 2017
SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation... May 08 2017
SHAREHOLDER ANNOUNCEMENT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class... May 08 2017
DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and... May 08 2017
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action... May 08 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... May 08 2017
MAY 8 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc.... May 05 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in... May 05 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of... May 05 2017
DEADLINE MONDAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... May 05 2017
MONDAY DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc.... May 04 2017
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit... May 04 2017
5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc.... May 03 2017
DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And... May 03 2017
DEADLINE ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and... May 02 2017
SCYX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... May 02 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... May 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat